Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 6Leukemia, Lymphocytic, Chronic, B-Cell 6Waldenstrom Macroglobulinemia 5Recurrence 5Lymphoma, Mantle-Cell 5Lymphoma, Follicular 4Lymphoma 2Leukemia 2B-cell Malignancies 2Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1

Interventions

zanubrutinib 2itacitinib 1Voriconazole 1INCB039110 1Fluconazole 1Diltiazem 1Clarithromycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × B-cell Malignancies × zanubrutinib × Clear all
NCT04551963 2024-10-26

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

BeiGene

Phase 1 Completed
26 enrolled 20 charts
Lymphoid

B-cell Malignancies

NCT02343120 2022-04-28

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

BeiGene

Phase 1/2 Completed
385 enrolled 29 charts 2 FDA
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡